News

TOP 314 | See the most profitable retailers in Estonia

According to last year's results, the top ten companies with the highest profitability in the retail trade included mainly companies dealing in fashion and interior goods, but regardless of difficult times, also retailers in a specific field.

Authors: Marion Lehes Kaubandus.ee editor; Maarit Eerme Kaubandus.ee manager

Äripäev - kaubandus.ee

 ...

HansaBioMed Life Sciences, the most profitable retail company, received the second place in TOP, which, in addition to production, sells products and services that help researchers study and isolate exosomes - tiny particles released by cells that carry information and are of significant importance in diagnostics, therapeutic development and personalized medicine. They are also becoming popular in the fields of cosmetic and aesthetic medicine.

"Our main success can be attributed to the growth of exosome science in the last decade," said company manager Paolo Guazzi. The company also delivers in Asia and America. "We tried to bypass the limitations of traditional retail sales by using e-commerce. We focus on B2B sales, establishing long-term contracts and relationships with large companies or new companies entering the field of nanoparticles and looking for expertise,” explained the manager.

He added that if, on the one hand, the growth of the field of exosomes is predicted , it must be taken into account that new competitors approach this field every year. "Operating in such a dynamic industry requires us to remain adaptable and innovative and always ready to evolve and diversify, while being aware of our strengths and limitations," explained the manager.

...

Read the full article in Estonian here

HansaBioMed Life Sciences launches Purified Extracellular Vesicles from Human Platelets, developed in collaboration with Finnish Red Cross Blood Service.

Tallinn, Estonia – [03/09/2024] – HansaBioMed Life Sciences, a pioneer in the field of extracellular vesicles (EVs), is proud to announce the launch of its latest product: purified Extracellular Vesicles from Human Platelets. This product, developed in collaboration with the Finnish Red Cross Blood Service (FRCBS), represents a significant advancement in the standardization, control, and purity of EVs from human biofluids available on the market.

The partnership between HansaBioMed and FRCBS, which began in 2021, was established with the shared goal of offering highly characterized and standardized EV material from Blood components to the life science research and development. The newly released EVs from Human Platelets set a new benchmark in the field, offering researchers superior quality and reliability compared to existing EV products.

Application note:

Tangential Flow Filtration for efficient depletion of nanoparticles contained in Fetal Bovine Serum

Sirin Korulu Koc, Jevgenia Dõrina, Paolo Guazzi; HansabioMed Life Sciences

Fetal Bovine Serum (FBS) or Fetal Calf Serum (FCS) are commonly used supplements in cell culture media.
However, using FBS, nanoparticles of bovine origin, such as lipoproteins and EVs, are introduced into the culture medium, where they not only can modulate the signaling of the recipient cells but also contaminate the cell-derived vesicle preparation, co-isolating with them during the EV purification phase.
To date, several supplements or EV depleted sera are commercially available, as well as several protocols have been developed to remove FBS nanoparticles, mainly based on ultrafiltration or ultracentrifugation methods.
In this application note, we show how our TFF-EVs can be used to remove nanoparticles from FBS in one single filtration shot, working directly under the safety cabinet. A simple, fast and inexpensive way to drastically reduce the presence of nanoparticles in FBS, without impacting the cell growth and viability, and by preserving the sterility.

HansaBioMed Life Sciences and Finnish Red Cross Blood Service start a join effort forHansaBioMed Life Sciences and Finnish Red Cross Blood Service start a join effort fordeveloping next generation of Extracellular Vesicles from donated blood as referencematerial for researchers.

The new cooperation is set under the heads of agreement and is aimed to offer highly characterized andstandardized EV material for life science market to further accelerate the development of the EV applications indiagnostics and therapy.